comparemela.com

Latest Breaking News On - Area lead oncology - Page 1 : comparemela.com

ESMO 2023: Janssen reveals data for intravesical delivery system

ESMO 2023: Janssen reveals data for intravesical delivery system
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Martin vogelAndrea necchiJanssen cilag gmbEuropean society for medical oncologyScientific instituteJanssen pharmaceutical companies of johnsonSalute san raffaele universityBacillus calmette guPharmaceutical companiesEuropean societyMedical oncologyVita salute san raffaele universityRaffaele hospitalArea lead oncologyJanssen cilag gmbh

First Results with Erdafitinib-Releasing Intravesical

Investigational TAR-210 first-in-human results highlight the potential for local sustained release of erdafitinib with a novel intravesical delivery.

Comunidad autonoma de catalunaRegion flamandeIndianj urolJanssen cilag gmbJanssen pharmaceuticaJeffrey infanteMartin vogelUrology care foundationJanssen research developmentNone of the janssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonEuropean society for medical oncologyAstex therapeuticsOncology early clinical developmentTranslational researchAstex announces new drug discovery alliance

Results from Phase 2 THOR-2 Study Showed Improved Rates of

Data from Cohort 1 of the Phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical.

Region flamandeUnited kingdomJanssen cilag gmbIndianj urolKiran patelJames wf cattoMartin vogelJanssen pharmaceuticaAstex announces new drug discovery allianceUniversity of sheffieldClinical developmentJanssen researchNone of the janssen pharmaceutical companiesExchange commissionJanssen pharmaceutical companiesDrug administration

Johnson & Johnson : Janssen Aims to Define New Standards of Care in the Treatment of Solid Tumor Cancers with Transformative Data Planned for Presentation at ESMO -October 16, 2023 at 08:33 am EDT

News Release Media Contacts: Brian Kenney +1 215-620-0111 Suzanne Frost +1.

Janssen cilag gmbPeter lebowitzMartin vogelJanssen research developmentGlobal therapeutic area headJanssen researchArea lead oncologyPresidential symposium

European Approval Sought for Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC

A Type II extension of indication application seeking the approval of amivantamab in combination with carboplatin and pemetrexed for the frontline treatment of adult patients with advanced non–small cell lung cancer and activating EGFR exon 20 insertion mutations has been submitted to the European Medicines Agency.

Janssen cilag gmbMartin vogelKiran patelJanssen research developmentEuropean medicines agency for rybrevantEuropean medicines agencyDrug administrationJanssen pharmaceutical companies of johnsonEuropean commissionArea lead oncologyJanssen cilag gmbhJanssen researchJanssen pharmaceutical companiesEpidermal growth factor receptorEgfr exon 20 insertion mutationNon small cell lung cancer nsclc

vimarsana © 2020. All Rights Reserved.